Multiple γ-secretase product peptides are coordinately increased in concentration in the cerebrospinal fluid of a subpopulation of sporadic Alzheimers disease subjects

Molecular Neurodegeneration

Volumn 7, Issue 1, 2012, Pages

  Hata, Saori ^a   Taniguchi, Miyako ^b   Piao, Yi ^a   Ikeuchi, Takeshi ^c   Fagan, Anne M ^d   Holtzman, David M ^d   Bateman, Randall ^d   Sohrabi, Hamid R ^e,f   Martins, Ralph N ^e   Gandy, Sam ^g,h   Urakami, Katsuya ^b   Suzuki, Toshiharu ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b TOTTORI UNIVERSITY   (Japan)

^c NIIGATA UNIVERSITY   (Japan)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e EDITH COWAN UNIVERSITY   (Australia)

^f HOLLYWOOD PRIVATE HOSPITAL   (Australia)

^g MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^h VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

amyloid; secretase; Alcadein; Alzheimer's disease; Cerebrospinal fluid

Indexed keywords

ALCADEIN ALPHA; AMYLOID BETA PROTEIN[1-40]; AMYLOID PRECURSOR PROTEIN; GAMMA SECRETASE; MEMBRANE PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN CLEAVAGE; PROTEIN METABOLISM;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; BIOLOGICAL MARKERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED;

EID: 84862183317     PISSN: None     EISSN: 17501326     Source Type: Journal    
DOI: 10.1186/1750-1326-7-16     Document Type: Article

References (32)

1. Novel cadherin-related membrane proteins, Alcadeins, enhance the X11-like protein mediated stabilization of amyloid -protein precursor metabolism. Araki Y, Tomita S, Yamaguchi H, Miyagi N, Sumioka A, Kirino Y, Suzuki T, J Biol Chem 2003 278 49448 49458 10.1074/jbc.M306024200 12972431
2. Coordinated metabolism of Alcadein and amyloid -protein precursor regulates FE65-dependent gene transactivation. Araki Y, Miyagi N, Kato N, Yoshida T, Wada S, Nishimura M, Komano H, Yamamoto T, De Strooper B, Yamamoto K, Suzuki T, J Biol Chem 2004 279 24343 24354 10.1074/jbc.M401925200 15037614 (Pubitemid 38725297)
3. Regulation of amyloid -protein precursor by phosphorylation and protein interactions. Suzuki T, Nakaya T, J Biol Chem 2008 283 29633 29637 10.1074/jbc.R800003200 18650433
4. Molecular genetics of Alzheimer's disease. St George-Hyslop PH, Biol Psychiatry 2000 47 183 199 10.1016/S0006-3223(99)00301-7 10682216 (Pubitemid 30077395)
5. Alcadein cleavages by APP - and -secretases generate small peptides p3-Alcs indicating Alzheimer disease-related -secretase dysfunction. Hata S, Fujishige S, Araki Y, Kato N, Araseki M, Nishimura M, Hartmann D, Saftig P, Fahrenholz F, Taniguchi M, Urakami K, Akatsu H, Martins RN, Yamamoto K, Maeda M, Yamamoto T, Nakaya T, Gandy S, Suzuki T, J Biol Chem 2009 284 36024 36033 10.1074/jbc.M109.057497 19864413
6. St George-Hyslop PH: Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Sherrington R, Rogaev EI, Liang Y, Rogaeva EA, Levesque G, Ikeda M, Chi H, Lin C, Li G, Holman K, Tsuda T, Mar L, Foncin JF, Bruni AC, Montesi MP, Sorbi S, Rainero I, Pinessi L, Nee L, Chumakov I, Pollen D, Brookes A, Sanseau P, Polinsky RJ, Wasco W, Da Silva HA, Haines JL, Perkicak-Vance MA, Tanzi RE, Roses AD, Fraser PE, Rommens JM, Nature 1995 37 754 760
7. Familial Alzheimer's disease-linked presenilin 1 variants elevate A1-42/1-40 ratio in vitro and in vitro. Borchelt DR, Thinakaran G, Eckman CB, Lee MK, Davenport F, Ratovitsky T, Prada CM, Kim G, Seekins S, Yager D, Slunt HH, Wang R, Seeger M, Levey AI, Gandy SE, Copeland NG, Jenkins NA, Price DL, Younkin SG, Sisodia SS, Neuron 1996 17 1005 1013 10.1016/S0896-6273(00)80230-5 8938131 (Pubitemid 26424026)
8. Loss-of-function presenilin mutations in Alzheimer disease. De Strooper B, Taking point on the role of presenilin mutations in Alzheimer disease. EMBO Rep. 2007 8 141 146
9. Genetic and host factors for dementia in Down's syndrome. Schupf N, Br J Psychiatry 2002 180 405 410 10.1192/bjp.180.5.405 11983636 (Pubitemid 34499334)
10. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR, LaRossa GN, Spinner ML, Klunk WE, Mathis CA, DeKosky ST, Morris JC, Holtzman DM, Ann Neurol 2006 59 512 519 10.1002/ana.20730 16372280 (Pubitemid 43358072)
11. Beta amyloid in Alzheimer's disease: increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid. Grimmer T, Riemenschneider M, Förstl H, Henriksen G, Klunk WE, Mathis CA, Shiga T, Wester HJ, Kurz A, Drzezga A, Biol Psychiatry 2009 65 927 934 10.1016/j.biopsych.2009.01.027 19268916
12. Relationship of cerebrospinal fluid markers to 11C-PiB and 18F-FDDNP binding. Tolboom N, van der Flier WM, Yaqub M, Boellaard R, Verwey NA, Blankenstein MA, Windhorst AD, Scheltens P, Lammertsma AA, van Berckel BN, J Nucl Med 2009 50 1464 1470 10.2967/jnumed.109.064360 19690025
13. Human apoE isoforms differentially regulate brain amyloid- peptide clearance. Castellano JM, Kim J, Stewart FR, Jiang H, DeMattos RB, Patterson BW, Fagan AM, Morris JC, Mawuenyega KG, Cruchaga C, Goate AM, Bales KR, Paul SM, Bateman RJ, Holtzman DM, Sci Transl Med 2011 3 89ra57 10.1126/scitranslmed. 3002156 21715678
14. Alternative processing of -secretase substrates in common forms of mild cognitive impairment and Alzheimer's disease: Evidence for -secretase dysfunction. Hata S, Fujishige S, Araki Y, Taniguchi M, Urakami K, Peskind E, Akatsu H, Araseki M, Yamamoto K, Martins RN, Maeda M, Nishimura M, Levey A, Chung KA, Montine T, Leverenz J, Fagan A, Goate A, Bateman R, Holtzman DM, Yamamoto T, Nakaya T, Gandy S, Suzuki T, Ann Neurol 2011 69 1026 1031 10.1002/ana.22343 21681798
15. Neuroimaging Initiative TJ: Coordinated increase of -secretase products in the plasma of some female Japanese sporadic Alzheimer's disease patients: Quantitative analysis of p3-Alcwith a new ELISA system. Konno T, Hata S, Hamada Y, Horikoshi-Sakuraba Y, Nakaya T, Saito Y, Yamamoto T, Yamamoto T, Maeda M, Ikeuchi T, Gandy S, Akatsu H, Suzuki T, Mol Neurodegener 2011 6 76 10.1186/1750-1326-6-76 22067061
16. Plasma and cerebrospinal fluid levels of amyloid proteins 1-40 and 1-42 in Alzheimer disease. Mehta PD, Pirttila T, Mehta SP, Sersen EA, Aisen PS, Wisniewski HM, Arch Neurol 2000 57 100 105 10.1001/archneur.57.1.100 10634455 (Pubitemid 30027637)
17. Validation of Alzheimer's disease CSF and plasma biological markers: The multicentre reliability study of the pilot Europian Alzheimer's disease neuroimaging initiative (E-ADNI). Buerger K, Frisoni G, Uspenskaya O, Ewers M, Zetterberg H, Geroldi C, Binetti G, Johannsen P, Rossini PM, Wahlund LO, Vellas B, Blennow K, Hampel H, Exp. Geron 2009 44 579 585 10.1016/j.exger.2009.06.003
18. Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly. Fagan AM, Head D, Shah AR, Marcus D, Mintun M, Morris JC, Holtzman DM, Ann Neurol 2009 65 176 183 10.1002/ana.21559 19260027
19. Inverse relation between in vivo amtloid imaging load and cerebrosoinal fluid Abeta42 in humans. Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR, LaRossa GN, Spinner ML, Klunk WE, Mathis CA, DeKosky ST, Morris JC, Holtzman DM, Ann Neurol 2006 59 512 519 10.1002/ana.20730 16372280 (Pubitemid 43358072)
20. Testing the right target and right drug at the right stage. Sperling RA, Jack CR Jr, Aisen PS, Sci Transl Med 2011 3 111cm33 10.1126/scitranslmed.3002609 22133718
21. Revising the definition of Alzheimer's disease: a new lexicon. Dubois B, Feldman HH, Jacova C, DeKosky ST, Delacourte A, Fox NC, Galasko D, Gauthier S, Hampel H, Jicha GA, Meguro K, O'Brien J, Pasquier F, Robert P, Rossor M, Salloway S, Sarazin M, de Souza LC, Stern Y, Visser PJ, Scheltens P, Lancet Neurol 2010 9 1118 10.1016/S1474-4422(10)70223-4 20934914
22. Utility of plasma levels of soluble p3-Alcadein () as a biomarker for sporadic Alzheimer's disease. Kamogawa K, Kohara K, Tabara Y Y, Takita R, Miki T, Konno T, Hata S, Suzuki T, J Alzheimers Dis 2011
23. Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC, Yarasheski KE, Bateman RJ, Science 2010 330 1774 10.1126/science.1197623 21148344
24. Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. Hampel H, Frank R, Broich K, Teipel SJ, Katz RG, Hardy J, Herholz K, Bokde AL, Jessen F, Hoessler YC, Sanhai WR, Zetterberg H, Woodcock J, Blennow K, Nat Rev Drug Discov 2010 9 560 574 10.1038/nrd3115 20592748
25. Report of the task force on designing clinical trials in early (predementia) AD. Aisen PS, Andrieu S, Sampaio C, Carrillo M, Khachaturian ZS, Dubois B, Feldman HH, Petersen RC, Siemers E, Doody RS, Hendrix SB, Grundman M, Schneider LS, Schindler RJ, Salmon E, Potter WZ, Thomas RG, Salmon D, Donohue M, Bednar MM, Touchon J, Vellas B, Neurology 2011 76 280 286 10.1212/WNL. 0b013e318207b1b9 21178097
26. Frequent amyloid deposition without significant cognitive impairment among the elderly. Aizenstein HJ, Nebes RD, Saxton JA, Price JC, Mathis CA, Tsopelas ND, Ziolko SK, James JA, Snitz BE, Houck PR, Bi W, Cohen AD, Lopresti BJ, DeKosky ST, Halligan EM, Klunk WE, Arch Neurol 2008 65 1509 1517 10.1001/archneur.65.11.1509 19001171
27. The lack of accumulation of senile plaques or amyloid burden in Alzheimer's disease suggests a dynamic balance between amyloid deposition and resolution. Hyman BT, Marzloff K, Arriagada PV, J Neuropathol Exp Neurol 1993 52 594 600 10.1097/00005072-199311000-00006 8229078 (Pubitemid 23335735)
28. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock R, Klunk WE, Mathis CA, Blennow K, Barakos J, Okello AA, de Liano Rodriguez Martinez S, Liu E, Koller M, Gregg KM, Schenk D, Black R, Grundman M, Lancet Neurol 2010 9 363 372 10.1016/S1474-4422(10)70043-0 20189881
29. Modulation of gamma-secretase reduces beta-amyloid deposition in a transgenic mouse model of Alzheimer's disease. Kounnas MZ, Danks AM, Cheng S, Tyree C, Ackerman E, Zhang X, Ahn K, Nguyen P, Comer D, Mao L, Yu C, Pleynet D, Digregorio PJ, Velicelebi G, Stauderman KA, Comer WT, Mobley WC, Li YM, Sisodia SS, Tanzi RE, Wagner SL, Neuron 2010 67 769 780 10.1016/j.neuron.2010.08.018 20826309
30. Extreme cerebrospinal fluid amyloid beta levels identify family with late-onset Alzheimer's disease presenilin 1 mutation. Kauwe JS, Jacquart S, Chakraverty S, Wang J, Mayo K, Fagan AM, Holtzman DM, Morris JC, Goate AM, Ann Neurol 2007 61 446 53 10.1002/ana.21099 17366635 (Pubitemid 46878772)
31. Metalloproteinase/Presenilin1 processing of ephrinB regulates EphB-induced Src phosphorylation and signaling. Georgakopoulos A, Litterst C, Ghersi E, Baki L, Xu C, Serban G, Robakis NK, EMBO J 2006 25 1242 1252 10.1038/sj.emboj.7601031 16511561
32. Ligand binding and calcium influx induce distinct ectodomain/gamma- secretase-processing pathways of EphB2 receptor. Litterst C, Georgakopoulos A, Shioi J, Ghersi E, Wisniewski T, Wang R, Ludwig A, Robakis NK, J Biol Chem 2007 282 16155 16163 10.1074/jbc.M611449200 17428795 (Pubitemid 47100347)